AIMT - Aimmune down 7% on cautious ICER report on peanut allergy treatments July, 11 2019 10:31 AM Aimmune Therapeutics Inc. Aimmune Therapeutics (AIMT -6.5%) is down on below-average volume on the heels of a cautionary report on peanut allergy treatments by the non-profit Institute for Clinical and Economic Review (ICER).More news on: Aimmune Therapeutics, Inc., DBV Technologies S.A., Healthcare stocks news, Stocks on the move, Read more ...